Immunome (IMNM) Income from Continuing Operations (2019 - 2026)
Immunome (IMNM) posted Income from Continuing Operations of 244246000.0 for Q1 2026, down 234.11% on a QoQ basis from 73104000.0 in Q4 2025, and down 443.98% year-over-year from 71006341.37 in Q1 2025.
Immunome (IMNM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Immunome's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 244246000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 443.98% year-over-year to 244246000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 489556000.0 (down 48.11% YoY) and the FY2025 annual result came in at 404781000.0, up 1.88% from the prior year.
- Income from Continuing Operations was 244246000.0 for Q1 2026 at Immunome, down from 73104000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4571000.0 in Q1 2023 and bottomed at 244246000.0 in Q1 2026.
- A 5-year average of 66242411.76 and a median of 70303000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 2796.5% — and 2025, when it surged 66.09%.
- Immunome's Income from Continuing Operations stood at 8079000.0 in 2022, then plunged by 1071.79% to 94669000.0 in 2023, then advanced by 12.04% to 83269000.0 in 2024, then climbed by 12.21% to 73104000.0 in 2025, then sank by 234.11% to 244246000.0 in 2026.
- Business Quant data shows IMNM's Income from Continuing Operations at 244246000.0 in Q1 2026, 73104000.0 in Q4 2025, and 101903000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Immunome | 2.49 Bn | 1.91 Bn | - | -244.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -244.25 Mn |
| Dec 31, 2025 | -73.10 Mn |
| Sep 30, 2025 | -101.90 Mn |
| Jun 30, 2025 | -70.30 Mn |
| Mar 31, 2025 | -44.90 Mn |
| Dec 31, 2024 | -83.27 Mn |
| Sep 30, 2024 | -116.13 Mn |
| Jun 30, 2024 | -86.23 Mn |
| Mar 31, 2024 | -132.40 Mn |
| Dec 31, 2023 | -94.67 Mn |
| Sep 30, 2023 | -15.83 Mn |
| Jun 30, 2023 | -16.07 Mn |
| Mar 31, 2023 | -4.57 Mn |
| Dec 31, 2022 | -8.08 Mn |
| Sep 30, 2022 | -11.93 Mn |
| Jun 30, 2022 | -10.73 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -7.84 Mn |
| Sep 30, 2021 | -7.72 Mn |
| Jun 30, 2021 | -26.04 Mn |